Is Combination Therapy with Inhaled Anticholinergics and beta(2)-Adrenoceptor Agonists Justified for Chronic Obstructive Pulmonary Disease?
Chronic obstructive pulmonary disease (COPD) is a debilitating condition characterised by progressive, irreversible airflow limitation. The economic and social burden of the disease is enormous. The treatment of COPD is guided by the stage of the disease and is aimed primarily at control of symptoms. Bronchodilators are the cornerstone of pharmacological management of COPD. Short-acting bronchodilators (beta(2)-adrenoceptor agonists and anticholinergics) have been available for many years and have been extensively studied as individual agents and in combination. When administered in combination, short-acting bronchodilators provide superior bronchodilation compared with individual agents given alone. However, the improvement in bronchodilation does not translate into an improvement in quality-of-life (QOL) indices. More recently, long-acting beta(2)-adrenoceptor agonists (LABAs) and anticholinergics have been introduced, and current guidelines recommend regular use of these agents in C
Related Questions
- Is Combination Therapy with Inhaled Anticholinergics and beta(2)-Adrenoceptor Agonists Justified for Chronic Obstructive Pulmonary Disease?
- Should inhaled anticholinergics be added to beta2 agonists for treating acute childhood and adolescent asthma?
- Where do long acting beta 2 agonists and leukotriene antagonists fit into asthma therapy?
